A number of other analysts also recently issued reports on ONCE. William Blair initiated coverage on Spark Therapeutics in a research report on Wednesday, June 28th. They set an outperform rating for the company. Jefferies Group LLC initiated coverage on Spark Therapeutics in a research report on Monday, July 10th. They set a buy rating and a $85.00 price target for the company. Zacks Investment Research downgraded Spark Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 12th. ValuEngine downgraded Spark Therapeutics from a hold rating to a sell rating in a research report on Thursday, July 13th. Finally, Cantor Fitzgerald set a $94.00 price target on Spark Therapeutics and gave the company a buy rating in a research report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. Spark Therapeutics presently has an average rating of Buy and a consensus price target of $90.47.
Shares of Spark Therapeutics (ONCE) traded up 4.91% on Wednesday, reaching $84.97. The company’s stock had a trading volume of 460,780 shares. The stock’s market cap is $3.11 billion. Spark Therapeutics has a 12 month low of $35.07 and a 12 month high of $91.75. The firm’s 50-day moving average price is $85.11 and its 200-day moving average price is $85.11.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business’s revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.04) EPS. On average, analysts forecast that Spark Therapeutics will post ($7.59) earnings per share for the current fiscal year.
WARNING: “Spark Therapeutics, Inc. (ONCE) Earns “Buy” Rating from Royal Bank Of Canada” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/10/29/spark-therapeutics-inc-once-earns-buy-rating-from-royal-bank-of-canada.html.
In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $86.16, for a total value of $430,800.00. Following the transaction, the insider now directly owns 215,000 shares of the company’s stock, valued at approximately $18,524,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen W. Webster sold 2,337 shares of Spark Therapeutics stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $71.12, for a total value of $166,207.44. Following the completion of the transaction, the chief financial officer now directly owns 4,837 shares in the company, valued at $344,007.44. The disclosure for this sale can be found here. Insiders sold a total of 1,121,837 shares of company stock worth $94,360,267 over the last ninety days. Insiders own 7.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. increased its stake in Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics in the 2nd quarter worth approximately $143,000. BNP Paribas Arbitrage SA increased its stake in Spark Therapeutics by 530.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 2,449 shares during the period. Pacad Investment Ltd. increased its stake in Spark Therapeutics by 75.0% in the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC purchased a new position in Spark Therapeutics in the 1st quarter worth approximately $227,000. 77.29% of the stock is currently owned by institutional investors and hedge funds.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
What are top analysts saying about Spark Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics Inc. and related companies.